In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cystic Fibrosis: Successes, Opportunities And Challenges

Executive Summary

What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.


Related Content

Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace
Antibiotic Pipeline Profile: Targeting Delivery To Infection Site
One Size No Longer Fits All: The Personalized Medicine Trial Landscape
PTC Tumbles On Ataluren Failure In Cystic Fibrosis
Finance Watch: Surrozen Raises $33m In $483m February Flurry; Also, Are Reverse Mergers This Year's IPOs?
Vertex Sits On $1.4bn Cash, Seeks External Innovation Away From CF
Moderna Signs Single Drug Deal With CF Expert Vertex For Up To $315m
Australia thrashes out patient access deals for Soliris/Kalydeco
With Incivek Deflated, Vertex’s HCV Roller Coaster Ride Hinges On Phase II Candidate VX-135
Australian Kalydeco decision 'deferred,' patients will fight but need a champion


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts